Elicio Therapeutics (ELTX) Non-Current Assets (2020 - 2026)

Elicio Therapeutics has reported Non-Current Assets for 7 years, with the latest figure at $6.5 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 10.41% year-over-year to $6.5 million; the trailing twelve-month figure through Mar 2026 stood at $26.8 million (down 15.04% YoY), and the FY2025 full-year result was $6.6 million, down 12.48% from the prior year.
• Non-Current Assets for Q1 2026 stood at $6.5 million, down from $6.6 million in the prior quarter.
• The five-year high for Non-Current Assets was $11.9 million in Q4 2022, with the low at $1.1 million in Q1 2023.
• Historically, Non-Current Assets has averaged $7.6 million across 5 years, with a median of $7.2 million in 2025.
• Annual changes were most pronounced in 2023 — Non-Current Assets sank 77.29% — and 2024, when it soared 807.89%.
• Elicio Therapeutics' Non-Current Assets stood at $11.9 million in 2022, then decreased by 9.62% to $10.8 million in 2023, then tumbled by 30.68% to $7.5 million in 2024, then decreased by 12.48% to $6.6 million in 2025, then dropped by 0.95% to $6.5 million in 2026.
• The last three Non-Current Assets figures came in at $6.5 million (Q1 2026), $6.6 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.